Novartis keeps a close eye on gene therapy with Vedere Bio buyAlready a major player in gene therapy, Novartis has swooped on US startup Vedere Bio in a $280 Share XNovartis keeps a close eye on gene therapy with Vedere Bio buyhttps://pharmaphorum.com/news/novartis-keeps-a-close-eye-on-gene-therapy-with-vedere-bio-buy/
SparingVision raises €44.5m for retinitis pigmentosa gene therapyFrench biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare Share XSparingVision raises €44.5m for retinitis pigmentosa gene therapyhttps://pharmaphorum.com/news/sparingvision-raises-44-5-million-euros-for-retinitis-pigmentosa-gene-therapy/
Takeda to make $200m loss after Novartis’ dry-eye drug hits trouble in EuropeNovartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing Share XTakeda to make $200m loss after Novartis’ dry-eye drug hits trouble in Europehttps://pharmaphorum.com/news/takeda-to-make-200m-loss-after-novartis-dry-eye-drug-hits-trouble-in-europe/
Bausch + Lomb buys US rights to Stada’s Lucentis biosimilarBausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches Share XBausch + Lomb buys US rights to Stada’s Lucentis biosimilarhttps://pharmaphorum.com/news/bausch-lomb-buys-us-rights-to-stadas-lucentis-biosimilar/
UK court imposes safety rules on off-label use of Avastin in wet-AMDBayer has said a new UK court ruling could limit off-label use of Roche’s Avastin in ophthalmology by Share XUK court imposes safety rules on off-label use of Avastin in wet-AMDhttps://pharmaphorum.com/news/uk-appeal-court-upholds-use-of-avastin/
First patient dosed in trial of Allergan/Editas’ CRISPR blindness drugA first patient has been treated in a trial of an Allergan and Editas drug based on CRISPR/Cas9, Share XFirst patient dosed in trial of Allergan/Editas’ CRISPR blindness drughttps://pharmaphorum.com/news/first-patient-dosed-in-trial-of-allergan-editas-crispr-blindness-drug/
Novartis’ Beovu safety woes could cost billions of dollars, says analystThe launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several Share XNovartis’ Beovu safety woes could cost billions of dollars, says analysthttps://pharmaphorum.com/news/novartis-beovu-launch-could-be-hit-by-safety-warning/
More pressure on Bayer as EU approves Novartis’ Beovu in wet AMDThe market for ophthalmology drugs in Europe just got hotter with the approval of Novartis’ Beovu for neovascular Share XMore pressure on Bayer as EU approves Novartis’ Beovu in wet AMDhttps://pharmaphorum.com/news/more-pressure-on-bayer-as-eu-approves-novartis-beovu-in-wet-amd/
Verily plans digital ophthalmology joint venture with SantenVerily is planning a digital ophthalmology joint venture with Japan’s specialist in the field, Santen. The joint venture Share XVerily plans digital ophthalmology joint venture with Santenhttps://pharmaphorum.com/news/verily-plans-ophthalmology-joint-venture-with-santen/
